Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Paul Perreault
Age : 63
Public asset : 49,335,924 USD
Country of residence : Unknown
Linked companies : CSL Limited

Biography of Paul Perreault 
Currently, Paul Roger Perreault is Chief Executive Officer, Executive Director & MD at CSL Ltd. In his past career he held the position of Chairman-Global Board at Plasma Protein Therapeutics Association, Chief Executive Officer & Managing Director at CSL Behring LLC, Vice President & General Manager at Aventis Behring, Business Director at Wyeth-Ayerst Research and Vice President & General Manager at Aventis Bio-Services, Inc. Mr. Perreault received an undergraduate degree from the University of Central Florida.


Current positions of Paul Perreault 
Holdings of Paul Perreault 
Paul Perreault : Personal Network 
Most Read News 
05/11CATHIE WOOD : Tumble in Coinbase pushes Wood's ARK fund closer to pandemic low
RE
05/12MASAYOSHI SON : SoftBank Vision Fund posts $26 billion loss; Son pledges defence
RE
05/14ELON MUSK : Elon Musk says Twitter legal team told him he violated an NDA
RE
05/11ELON MUSK : Musk's delay in disclosing Twitter stake triggers SEC probe - WSJ
RE
05/20XAVIER NIEL : UWR shares spike as billionaire Xavier Niel discloses 27% stake
RE
05/19ELON MUSK : Musk says 'Tesla is on my mind 24/7' amid concerns about Twitter distraction
RE
05/10ELON MUSK : Elon Musk says Tesla open to buying a mining company
RE
05/17ELON MUSK : Prominent hedge funds invested in Twitter before Musk unveiled plans
RE
05/17JPMorgan shareholders vote disapproval of CEO Dimon's special payout
RE
05/06MARTIN SORRELL : Sorrell's S4 sees good 2022 after publishing delayed results
RE
More news


© 2022 People and Ownership :   
Paul Perreault : Connections 


Latest news about Paul Perreault 
02/15Australia biotech firm CSL says plasma business hit by Omicron, but demand robust
RE
02/15TRANSCRIPT : CSL Limited, H1 2022 Earnings Call, Feb 16, 2022
CI
02/15CSL 1st Half Net Profit Falls as Immunoglobulin Sales Decline
DJ
2021TRANSCRIPT : CSL Limited, Vifor Pharma AG - M&A Call
CI
2021CSL Makes US$11.7 Billion Offer for Switzerland's Vifor Pharma -- 2nd Update
DJ
2021CSL Makes US$11.7 Billion Offer for Switzerland's Vifor Pharma -- Update
DJ
2021Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln
RE
More news